Aldosterone Longevity-Medicine Target Ranges: What Your Lab Result Actually Means

What Is Aldosterone and Why Does It Matter for Longevity?

Aldosterone is a steroid hormone produced by the zona glomerulosa of the adrenal cortex. Its primary role is to bind mineralocorticoid receptors (MRs) in the kidney's collecting duct, directing sodium reabsorption and potassium excretion, which sets blood pressure. Beyond the kidney, MR activation in cardiac tissue, vascular smooth muscle, and the brain drives collagen deposition and oxidative stress at levels that shorten healthspan independent of blood pressure itself.

Why the Standard Reference Range Is Too Permissive

Most commercial laboratories report aldosterone as "normal" anywhere from 3 to 16 ng/dL in a sodium-replete, morning, seated collection. That range is derived from population statistics, not from cardiovascular outcome studies. The Cardiovascular Health Study (N=5,888) found that plasma aldosterone in the top quartile (above roughly 9 to 10 ng/dL) was associated with a significantly higher risk of incident hypertension and left ventricular hypertrophy compared with participants in the bottom two quartiles, even within values that fall inside the laboratory's normal band [1].

A 2021 meta-analysis published in the Journal of the American Heart Association (pooling six prospective cohorts, N=11,483) reported that each one-standard-deviation increment in aldosterone was associated with a 16% higher risk of atrial fibrillation (HR 1.16, 95% CI 1.07 to 1.25) [2].

The Mineralocorticoid Receptor as a Longevity Target

MR signaling accelerates three aging-adjacent processes: cardiac fibrosis, arterial stiffness, and neuroinflammation. Animal studies using MR-knockout models show lower markers of senescence and better preserved kidney function at 24 months compared to wild-type controls [3]. The clinical translation is not perfect, but data from the RALES trial (N=1,663) and EMPHASIS-HF trial (N=2,737) both confirmed that MR antagonism with spironolactone or eplerenone reduced all-cause mortality by 30% and 24%, respectively, in patients with reduced ejection fraction heart failure [4, 5]. This mortality benefit strongly implies that keeping aldosterone signaling low across a lifetime reduces cumulative organ damage.

Aldosterone Normal Range vs. Longevity-Medicine Optimal Range

Standard ranges describe who is sick today. Longevity-medicine targets describe where your biology needs to be to minimize 10-to-30-year risk accumulation.

Standard Laboratory Reference Intervals

Reference intervals vary by collection posture and sodium status:

| Condition | Typical Range | |---|---| | Upright (2 hr), sodium-replete | 4 to 31 ng/dL | | Supine (at least 30 min), morning | 3 to 16 ng/dL | | 24-hour urine aldosterone | 3 to 20 mcg/24 hr |

The Endocrine Society's 2016 Clinical Practice Guideline on primary aldosteronism uses a morning seated plasma aldosterone above 10 to 15 ng/dL as a threshold that justifies confirmatory testing when paired with a suppressed renin [6].

The Longevity-Medicine Target

Based on the cardiovascular outcome data cited above and on emerging longevity-medicine consensus, the HealthRX medical team applies the following framework when reviewing aldosterone results for patients not yet diagnosed with primary aldosteronism:

Optimal (longevity target): Plasma aldosterone <10 ng/dL (supine, morning, sodium-replete), with an ARR <20 (ng/dL per ng/mL/hr), and plasma renin activity (PRA) >0.5 ng/mL/hr (confirming the feedback axis is intact).

Acceptable but requiring monitoring: Aldosterone 10 to 16 ng/dL with ARR 20 to 30. Recheck in 6 months with dietary sodium audit and blood pressure optimization.

Actionable (warrants confirmatory testing): Aldosterone >15 ng/dL with ARR >30 regardless of blood pressure. Proceed to saline infusion or fludrocortisone suppression testing per Endocrine Society protocol [6].

The rationale: keeping aldosterone below 10 ng/dL appears to track with the lowest cardiovascular event rates in prospective cohorts, even though the laboratory flags nothing as abnormal until values exceed 16 ng/dL.

The Aldosterone-to-Renin Ratio (ARR): The Test That Actually Screens for Disease

A single aldosterone value is not sufficient. Renin and aldosterone move together under normal physiology. The ARR is the standard first-line screening test for primary aldosteronism, recommended by the Endocrine Society when any of six clinical triggers are present [6].

When to Order the ARR

The Endocrine Society's 2016 guideline recommends ARR screening in these situations [6]:

• Sustained blood pressure above 150/100 mmHg on three separate measurements
• Hypertension resistant to three antihypertensive drugs including a diuretic
• Hypertension controlled with four or more drugs
• Spontaneous or diuretic-induced hypokalemia (serum K <3.5 mEq/L)
• Adrenal incidentaloma discovered on imaging
• Family history of primary aldosteronism or early-onset hypertension (onset <40 years)
• Hypertension in a first-degree relative diagnosed with primary aldosteronism

How to Interpret the ARR

An ARR above 30 (ng/dL)/(ng/mL/hr) is the most widely accepted positive screening threshold, carrying a sensitivity of approximately 79 to 90% and specificity of 75 to 83% for primary aldosteronism confirmation in validation studies [7]. Some institutions use a lower cutoff of 20 for higher sensitivity, accepting more false positives to capture earlier disease.

A suppressed renin (<0.2 ng/mL/hr or <3.2 mU/L using direct renin concentration assays) combined with a frankly elevated aldosterone is highly suspicious even if the ARR calculation sits below 30 due to floor effects in the denominator.

Pre-Analytical Variables That Distort the ARR

Getting the blood draw right matters enormously. Spironolactone and eplerenone both falsely suppress the ARR by elevating renin; they must be held for at least four weeks before testing, and ideally six weeks [6]. Beta-blockers suppress renin and can falsely raise the ARR, producing false positives. ACE inhibitors and ARBs raise renin and can produce false negatives by lowering the ARR. The preferred antihypertensive agents during testing are verapamil extended-release and doxazosin, which have minimal effects on the renin-aldosterone axis.

Primary Aldosteronism: More Common Than Most Clinicians Expect

Primary aldosteronism (PA) is not a rare endocrine curiosity. A landmark 2017 paper by Buffolo et al. In Hypertension (N=1,125 consecutive hypertensive patients) reported a PA prevalence of 11.2% across all stages of hypertension [8]. In patients with resistant hypertension, prevalence estimates reach 17 to 23% [6].

Why PA Goes Undiagnosed

The average delay from onset of PA to diagnosis is approximately 9 years according to registry data compiled by the European Network for the Study of Adrenal Tumors (ENSAT) [9]. Most patients have normal or only mildly elevated serum potassium; only 9 to 37% of PA patients present with the classic finding of hypokalemia [6]. Without routine ARR screening in hypertensive patients, the diagnosis is simply not considered.

Cardiovascular Consequences of Undiagnosed PA

PA carries excess organ damage beyond what blood pressure elevation alone predicts. A prospective study by Milliez et al. In the Journal of the American College of Cardiology (N=124 PA patients vs. 465 matched essential hypertension controls) showed PA patients had a 4-fold higher rate of atrial fibrillation, 3.6-fold higher stroke rate, and 1.9-fold higher rate of non-fatal myocardial infarction despite similar 24-hour blood pressures [10]. The mechanism is direct MR-mediated fibrosis and endothelial injury, not pressure-dependent remodeling.

Confirmatory Testing After a Positive ARR Screen

A positive ARR does not equal a confirmed PA diagnosis. Confirmation requires demonstrating that aldosterone secretion cannot be suppressed by sodium loading.

Saline Infusion Test Protocol

The saline infusion test involves infusing 2 liters of isotonic saline (0.9% NaCl) over four hours while the patient remains supine. Plasma aldosterone is measured at baseline and at four hours. A post-infusion aldosterone <5 ng/dL effectively rules out PA. A level above 10 ng/dL confirms the diagnosis. Values between 5 and 10 ng/dL are indeterminate and require a second confirmatory test [6].

The Endocrine Society notes: "We recommend one of four confirmatory tests: oral sodium loading, saline infusion, fludrocortisone suppression, or captopril challenge. The choice should depend on cost, patient compliance, local expertise, and laboratory facilities" [6].

Fludrocortisone Suppression Testing

Fludrocortisone 0.1 mg every six hours for four days, combined with salt loading, should suppress upright plasma aldosterone to below 6 ng/dL in normal subjects. Failure to suppress confirms PA. This test is the most sensitive option but requires inpatient or very closely supervised ambulatory monitoring for hypokalemia and hypertensive crisis.

Adrenal Vein Sampling

Once PA is biochemically confirmed, adrenal vein sampling (AVS) determines whether excess aldosterone comes from a unilateral adenoma (surgically curable) or bilateral hyperplasia (medically managed with MR antagonists). AVS is technically demanding; success rates at experienced centers exceed 90%, compared with under 50% at low-volume institutions [6]. CT imaging alone misclassifies the subtype in up to 37.8% of cases per a meta-analysis by Kempers et al. In the Annals of Internal Medicine [11].

Treatment Targets and How They Shift Outcomes

Treatment goals differ based on subtype. For both subtypes, the metabolic and cardiovascular outcome target is aldosterone signaling at or below the longevity-medicine threshold described above.

Unilateral Adrenalectomy for Adenoma

Laparoscopic unilateral adrenalectomy achieves biochemical cure (ARR normalization) in 94 to 100% of patients with confirmed unilateral disease [6]. Clinical cure, defined as resolution of hypertension off medication, occurs in approximately 35 to 60% of patients; the remainder require fewer antihypertensives than before surgery. A 2016 multicenter outcome study published in JAMA Surgery (N=705 patients from the PASO trial) found that complete clinical success occurred in 37% and partial success in 47% at one year post-adrenalectomy [12].

Mineralocorticoid Receptor Antagonist Therapy for Bilateral Disease

Spironolactone (starting dose 12.5 to 25 mg daily, titrating to a maximum of 100 mg daily) or eplerenone (25 to 50 mg twice daily) are the recommended medical treatments. The Endocrine Society's guideline endorses starting with spironolactone as first-line [6]. Titrate the dose to normalize serum potassium and blood pressure. Plasma aldosterone may remain elevated because MR antagonists are not suppressants; the ARR cannot be used to monitor treatment response once therapy begins. Instead, follow blood pressure, serum potassium, and renal function (eGFR and creatinine) at four to six weeks after each dose change.

Dietary Sodium and Aldosterone Suppression

Even in patients without PA, dietary sodium intake modifies aldosterone output. A sodium intake above 3,400 mg per day (the U.S. Average) provides enough substrate to chronically stimulate aldosterone at the higher end of the reference range. Reducing sodium intake to 1,500 to 2,000 mg per day can lower plasma aldosterone by 2 to 5 ng/dL in sodium-sensitive individuals, as demonstrated in a feeding study in normotensive adults [13]. Potassium intake above 3,500 mg per day also attenuates aldosterone secretion through feedback effects on the zona glomerulosa.

How to Collect the Aldosterone Test Correctly

A mishandled specimen produces a clinically useless result. These steps apply to both diagnostic and monitoring draws.

Preparation Requirements

• Maintain a normal-sodium diet (at least 100 mEq sodium/day, roughly 2,300 mg) for at least three days before the draw. A low-sodium diet suppresses renin and inflates the ARR.
• Draw the sample in the morning, between 8:00 and 10:00 AM.
• Remain ambulatory (seated or upright) for at least two hours before the draw to reflect physiologic diurnal conditions for the upright reference range.
• Hold spironolactone, eplerenone, and amiloride for six weeks. Hold beta-blockers, central alpha agonists (clonidine), and NSAIDs for at least two weeks if clinically safe.
• Confirm sample handling: plasma aldosterone is measured in EDTA tubes on ice, transported to the lab within 30 minutes of collection, or centrifuged and frozen at minus 20 degrees Celsius if transport is delayed.

Reference Ranges by Assay Type

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) assays are more specific than older immunoassay platforms and tend to produce slightly lower absolute values. When comparing serial results, always confirm the same assay method was used. A shift from immunoassay to LC-MS/MS may drop apparent aldosterone by 15 to 25%, which is a laboratory artifact rather than a physiologic change.

Interpreting Low Aldosterone: When Suppression Becomes a Problem

Low aldosterone is not automatically a favorable finding. Adrenal insufficiency, hyporeninemic hypoaldosteronism (common in diabetic nephropathy), and over-treatment with MR antagonists all present with plasma aldosterone below 3 ng/dL combined with elevated renin and hyperkalemia.

Patients on ACE inhibitors, ARBs, or direct renin inhibitors, particularly those with an eGFR below 45 mL/min/1.73m2 and type 2 diabetes, carry a measurable risk of developing clinically significant hyperkalemia from aldosterone suppression. The ONTARGET trial (N=25,620) reported that dual RAS blockade (ramipril plus telmisartan) produced a 2.2-fold higher risk of dialysis compared with either agent alone, largely through aldosterone-mediated potassium retention [14]. In longevity medicine, the target is not maximal aldosterone suppression but optimized signaling: enough aldosterone activity to maintain normokalemia and normal blood pressure without the chronic fibrotic overstimulation seen in PA.

Aldosterone and the Broader Adrenal Longevity Panel

Aldosterone does not exist in isolation. A complete adrenal evaluation in a longevity context includes plasma aldosterone, PRA or direct renin concentration, serum potassium, 24-hour urine cortisol, DHEA-S, and morning serum cortisol. Taken together, these markers characterize the balance between the mineralocorticoid and glucocorticoid axes, both of which drive accelerated tissue aging when dysregulated.

Low DHEA-S combined with high-normal aldosterone signals adrenal aging with relative mineralocorticoid excess, a pattern increasingly recognized in metabolic syndrome and cardiovascular disease [15]. Correcting that imbalance, first through dietary and lifestyle measures, then through pharmacologic MR antagonism if indicated, forms the core of adrenal-targeted longevity protocols.

If your morning aldosterone comes back above 10 ng/dL with a suppressed renin, order a full ARR panel and discuss screening for PA with your HealthRX clinician before your next scheduled follow-up.